Latest Hospitality News

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Medical Developments International reported a robust Q3 FY25 with $8.9 million revenue and $1.7 million operating cashflow, driven by strong Penthrox demand and pricing. New distribution agreements in France and Switzerland position the company for further European expansion.

Murray Cod Australia Ltd reports a remarkable 192% biomass increase, setting the stage for expanded domestic and international sales from May 2025. The company also advances sustainability certifications and strengthens its board to support growth.

Endeavour Group has appointed Jayne Hrdlicka as its new Managing Director and CEO, set to begin in January 2026, signaling a strategic push for growth and transformation under seasoned leadership.

Micro-X Ltd has secured a $5.6 million strategic partnership with Malaysian firm Billion Prima and raised $4 million in capital, marking a pivotal shift towards medical imaging while progressing key security and health technology projects.

Race Oncology has opened a second Australian clinical site for its Phase 1 trial of RC220 combined with doxorubicin in advanced solid tumours, aiming to speed patient enrolment and gather critical safety and efficacy data.

Alcidion Group Limited reported a robust Q3 FY25 with $13.1 million in cash receipts and a landmark 10-year $37.5 million contract with North Cumbria NHS Trust, prompting an upgrade to its full-year EBITDA guidance.

TruScreen has launched a landmark five-year cervical cancer screening program in Ho Chi Minh City, targeting 260,000 women with its AI-driven, non-invasive technology to boost screening rates and support Vietnam’s national health goals.

Eumundi Group has officially been acquired by SEQ Hospitality Group, with shareholders receiving A$1.62 per share and significant board changes announced. The company is set to be delisted from the ASX imminently.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.